Ardent Health (NYSE:ARDT) Posts Earnings Results, Misses Expectations By $0.03 EPS

Ardent Health (NYSE:ARDT) announced its quarterly earnings results on Wednesday. The company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.35 by ($0.03), FiscalAI reports. The firm had revenue of $1.61 billion for the quarter, compared to the consensus estimate of $1.63 billion. Ardent Health had a net margin of 3.24% and a return on equity of 19.02%. Ardent Health updated its FY 2026 guidance to 0.900-1.270 EPS.

Ardent Health Stock Performance

ARDT traded up $0.18 during midday trading on Wednesday, reaching $9.59. The company had a trading volume of 368,054 shares, compared to its average volume of 401,265. The business has a 50-day moving average of $8.98 and a two-hundred day moving average of $11.05. The company has a quick ratio of 1.95, a current ratio of 2.08 and a debt-to-equity ratio of 0.67. Ardent Health has a 1 year low of $8.07 and a 1 year high of $15.48. The company has a market cap of $1.37 billion, a P/E ratio of 6.61, a P/E/G ratio of 5.22 and a beta of 0.46.

Key Stories Impacting Ardent Health

Here are the key news stories impacting Ardent Health this week:

• Positive Sentiment: Ardent confirmed it will participate in March investor conferences — a chance for management to engage with investors and address the receivables/accounting issues directly, which could help calm markets if management provides clear updates. Ardent Health to Participate in March Investor Conferences
• Neutral Sentiment: One firm (Faruqi & Faruqi) cited a later April 21, 2026 deadline for lead‑plaintiff applications — a different date than many other notices — which may prolong headline risk and create scheduling/coordination uncertainty for potential plaintiffs. ARDT SHAREHOLDER REMINDER
• Negative Sentiment: Multiple national law firms (Hagens Berman, RGRD, Bronstein Gewirtz, Levi & Korsinsky, Rosen, Kahn Swick & Foti, Bleichmar Fonti & Auld, others) are actively soliciting Ardent investors to join or lead a securities class action tied to disclosures covering July 18, 2024–Nov 12, 2025; that cascade of notices increases litigation risk and ongoing headline pressure. MONDAY DEADLINE: Ardent Health, Inc. Investors…
• Negative Sentiment: Hagens Berman and others point to an alleged ~$97M “accounting shock” tied to Ardent’s use of a rigid “180‑day cliff” to reserve for uncollectible accounts — an approach the complaints say contradicts prior statements about detailed historical collection reviews. That specific allegation is the core catalyst for the prior ~33% stock drop and could lead to financial restatements, reserves, or regulatory scrutiny. ARDT WRITE OFFS: Hagens Berman Investigating Claims…

Institutional Trading of Ardent Health

Several institutional investors and hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd lifted its stake in shares of Ardent Health by 1,177.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,862 shares of the company’s stock valued at $25,000 after buying an additional 2,638 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Ardent Health during the third quarter valued at about $61,000. New York State Common Retirement Fund lifted its position in shares of Ardent Health by 121.4% in the second quarter. New York State Common Retirement Fund now owns 6,200 shares of the company’s stock valued at $85,000 after acquiring an additional 3,400 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Ardent Health in the third quarter worth about $145,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Ardent Health during the fourth quarter worth about $147,000.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ARDT. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ardent Health in a report on Monday, December 29th. Stephens lowered their price objective on shares of Ardent Health from $21.00 to $17.00 and set an “overweight” rating on the stock in a research report on Friday, November 14th. Guggenheim cut their target price on shares of Ardent Health from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Wall Street Zen lowered shares of Ardent Health from a “buy” rating to a “hold” rating in a research note on Sunday, November 23rd. Finally, Leerink Partners set a $16.00 price target on Ardent Health in a research note on Friday, November 14th. Six research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Ardent Health presently has an average rating of “Hold” and an average price target of $14.58.

About Ardent Health

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.